Hepatic enhancement and metastatic lesion conspicuity on CT scans: influence of intravenous glucagon and oral CT contrast material.
Hepatic enhancement and metastatic lesion conspicuity on CT scans: influence of intravenous glucagon and oral CT contrast material.
复制标题
CT 扫描上肝脏强化和转移病灶的明显性：静脉注射胰高血糖素和口服 CT 造影剂的影响。
DOI：
10.1148/radiology.202.2.9015064
复制
发表时间：
1997
期刊：
影响因子：
19.7
通讯作者：
Lee,JK
中科院分区：
文献类型：
--
作者：
Warshauer,DM;Wehmueller,MD;Molina,PL;Muller,KE;DeLuca,MC;Lee,JK
目的：确定胰高血糖素和口服造影剂对肝增强和转移灶的影响，明确CT扫描（CT）scans.MATERIALS AND METHODSNine肝转移病史的患者进行了两次CT检查，静脉注射造影剂。每例患者口服CT造影剂进行首次检查。在第二次检查中未给予口服造影剂。5例患者在静脉注射1 mg胰高血糖素的情况下进行了首次CT检查;在未使用胰高血糖素的情况下进行了第二次检查。4例患者在第二次检查前给予胰高血糖素，但在第一次检查前未给予胰高血糖素。肝脏、门静脉和主动脉的衰减由观察者测量，观察者不知道患者是否接受了胰高血糖素。病灶的清晰度以连续的尺度来评定。口服造影剂的患者（平均52 HU）与未口服造影剂的患者（平均47 HU; P = 0.019）相比，在扫描中观察到更大的平均肝脏强化。胰高血糖素与更大的肝脏增强无关。口服造影剂和胰高血糖素对病变的显着性都没有显著影响。CONCLUSION口服CT造影剂与肝脏增强的小幅增加相关，但在临床上并不重要。胰高血糖素似乎不影响人类肝脏增强或病变的显著性。
PURPOSETo determine the effect of glucagon and orally administered contrast material on hepatic enhancement and metastatic lesion conspicuity on computed tomographic (CT) scans.MATERIALS AND METHODSNine patients with a history of hepatic metastasis underwent two CT examinations with intravenously administered contrast material. Each patient was given orally administered CT contrast material for the first examination. No oral contrast material was given in the second examination. Five patients underwent the initial CT with intravenous administration of 1 mg of glucagon; the second examination was performed without glucagon. Four patients were administered glucagon before the second examination, but no glucagon was administered before the first. Attenuation in the liver, portal vein, and aorta was measured by observers blinded to whether the patient had been given glucagon. Lesion conspicuity was rated on a continuous scale.RESULTSGreater mean hepatic enhancement was noted on scans of patients in whom oral contrast material was administered (mean, 52 HU) versus those in whom no oral contrast material was administered (mean, 47 HU; P = .019). Glucagon was not associated with greater hepatic enhancement. Neither oral contrast material nor glucagon had a significant effect on lesion conspicuity.CONCLUSIONOral CT contrast material is associated with a small increase in hepatic enhancement that does not appear to be clinically important. Glucagon does not appear to affect hepatic enhancement or lesion conspicuity in humans.